296 related articles for article (PubMed ID: 12421428)
1. Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin.
Herz M; Arora V; Sun B; Ferguson SC; Bolli GB; Frier BM
Diabet Med; 2002 Nov; 19(11):917-23. PubMed ID: 12421428
[TBL] [Abstract][Full Text] [Related]
2. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
Roach P; Trautmann M; Arora V; Sun B; Anderson JH
Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
[TBL] [Abstract][Full Text] [Related]
3. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
[TBL] [Abstract][Full Text] [Related]
4. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus.
Roach P; Arora V; Campaigne BN; Mattoo V; Rangwala S;
Diabetes Obes Metab; 2003 Sep; 5(5):311-6. PubMed ID: 12940868
[TBL] [Abstract][Full Text] [Related]
5. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
6. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
7. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
Ahmed AB; Home PD
Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
[TBL] [Abstract][Full Text] [Related]
8. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
9. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes.
Roach P; Strack T; Arora V; Zhao Z
Int J Clin Pract; 2001 Apr; 55(3):177-82. PubMed ID: 11351771
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
Roach P; Woodworth JR
Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
12. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
13. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
14. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?
Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR
Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107
[TBL] [Abstract][Full Text] [Related]
15. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal.
Del Sindaco P; Ciofetta M; Lalli C; Perriello G; Pampanelli S; Torlone E; Brunetti P; Bolli GB
Diabet Med; 1998 Jul; 15(7):592-600. PubMed ID: 9686700
[TBL] [Abstract][Full Text] [Related]
16. A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes.
Roach P; Woodworth J; Gudat U; Cerimele B; Diebler F; Pein M; Dreyer M
Diabet Med; 2003 Nov; 20(11):946-52. PubMed ID: 14632722
[TBL] [Abstract][Full Text] [Related]
17. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
Schernthaner G; Kopp HP; Ristic S; Muzyka B; Peter L; Mitteregger G
Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Jan; 23(1):46-52. PubMed ID: 16409565
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.
Gale EA
Diabet Med; 2000 Mar; 17(3):209-14. PubMed ID: 10784225
[TBL] [Abstract][Full Text] [Related]
20. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
